2016 ACVIM Forum Research Abstract Program

Twenty-five cases were included. Stages included T1 (n = 1), T2 (n = 10), T3 (n = 2), T4 (n = 12). None had evidence of distant metastasis. Nineteen had regional lymph node aspirates and metastasis was present in one. Tumor types included adenocarcinomas (n = 15), chondrosarcomas (n = 5), transitional nasal carcinomas (n = 3), intranasal squamous cell carcinoma (n = 1), and neuroesthesioblastoma (n = 1). Clinical signs improved in all cases. Twelve cases had recheck CT scans 3-4 months post-SRT and partial or complete tumor response was seen in all cases. Minimal acute toxicity was detected. The only late effect noted to date is oronasal fistula development in one dog 4 months post-SRT (this was anticipated due to tumor invasion into the palate at diagnosis). The median disease progression-free survival time has not been reached, and 52% of dogs are progression-free at 1 year. Nine dogs are deceased (median survival time 375 days) and 40% are alive 600 days post SRT.